Sangamo BioSciences | SGMO - أصول متداولة





أصول متداولة تغيير تاريخ
Alaunos Therapeutics USD 970K 1.02M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Alterity Therapeutics Limited AUD 37.91M 15.92M 2025-12
Amgen USD 31.48B 2.42B 2026-03
Bayer EUR 35.3B 2.39B 2026-03
BioCryst Pharmaceuticals USD 373.62M 30.72M 2026-03
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Cipla INR 241.47B 7.71B 2026-03
Clal Biotechnology ILS 14.69M 1.95M 2023-12
Compugen USD 148.02M 59.1M 2025-12
CSL USD 11.85B 1000K 2025-12
Gilead Sciences USD 18.64B 1.25B 2026-03
GlaxoSmithKline GBP 17.76B 251M 2026-03
Grifols EUR 5.96B 316.31M 2025-12
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
J&J USD 59.17B 3.55B 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
Merck USD 35.02B 8.5B 2026-03
Novartis USD 26.61B 3.85B 2026-03
Omeros USD 69.65M 26.53M 2025-06
Pfizer USD 42.82B 76M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 30.16B 789M 2026-03
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Tectonic Therapeutic USD 239.89M 17.47M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03